|
New Insights about Platinum Sensitivity An important set of data is typified in the results of the Harvard team of Chee-Onn Leong and Leif Ellisen6 who found that triple negative cancers independently share the cisplatin sensitivity of BRCA1-associated tumors (even in those without BRCA mutations), a sensitivity that is mediated by activation of a proapoptotic (inducing programmed cell suicide) molecular pathway p53 family member (called TAp73), and from this and other studies it appears that p53 is what fundamentally mediates the apoptosis induced by DNA-damaging agents.
Extending these findings John Chia's team7 conducted a retrospective analysis to determine the response rates of such patients treated with paclitaxel and carboplatin (TC) chemotherapy, finding that TC induces a high response rate in patients with metastatic / recurrent triple negative disease, even for patients with prior exposure to taxanes and moreover, and impressively, even for those with large volume disease.
Collectively, therefore data from preclinical and clinical studies indicate that both BRCA1 and triple negative tumors have unique sensitivities to platinum agents such as cisplatin and carboplatin, as well as to the genotoxic biological agents, the PARP (poly(ADP-ribose)polymerase) inhibitors, and these observations are helping to guide a new series of clinical trials, and at least as importantly, helping to hone and optimize the treatment of triple negative disease, and suggest for instance that adding platinum agents to taxane chemotherapy may induce high levels of efficacy for triple negative disease.
Dear Jason,
I hope the above explains the reason why one doctor is considering a platinum agent. Your wife is BRCA1 positive.
Dose Dense AC + T has been the "gold standard" used for the last couple of years. The more current trend is AC x 4 followed by Taxol weekly for 12 weeks (it is more tolerable for side effects) and when studied against giving it every 3 weeks it was found to be more effective - (no trials were done with it being given every 2 weeks). Triple Negative is aggressive, and sneaky and the current thinking is to hit it hard right from the starting gait. I am sure bilateral mastectomies and bilateral ovary removal were also mentioned to your wife since she is BRCA1 positive. Is the chemotherapy tough for some - yes, but for others not. Given enough support, treatment for side effects, your dear wife will be able to do whatever treatment plan she decides on....and we will be here for you every step of the way.
I think it would be a good idea to ask each oncologist why they proposed the chemotherapy regimen they presented as options.
If you have any more questions or thoughts you went to discuss - please write again.
Love,
Connie
|